Phd in MOLECULAR MEDICINE

email: laura.dimagno@uniroma1.it
phone: 0649255155
building: RM110
room: 206/207

CURRENT POSITION
Tenure Track Researcher (RTT) - Settore scientifico-disciplinare: MEDS-02/A; Gruppo scientifico-disciplinare: 06/MEDS-02

DEPARTMENT
Department of Molecular Medicine, “Sapienza” University of Rome

EDUCATION AND CAREER
May 2024 – Date: Tenure track researcher at the Department of Molecular Medicine "Sapienza" University of Rome - Italy.
April 2024: Post-doctoral fellow at Istituto Pasteur - Fondazione Cenci Bolognetti, Rome - Italy.
April 2022 – March 2024: Post-doctoral fellow at Fondazione Umberto Veronesi - Italy.
May 2020 - March 2022: Research fellow - Department of Molecular Medicine - "Sapienza" University of Rome - Italy.
January 2020 - April 2020: Post-doctoral fellow at Istituto Pasteur - Fondazione Cenci Bolognetti, Rome - Italy.
July 2014 – December 2019: Post-doctoral fellow at Italian Institute of Technology, Center for Life Nano Sciences@Sapienza, Rome - Italy.
June 2013 - June 2014: Post-doctoral fellow at Istituto Pasteur - Fondazione Cenci Bolognetti, Rome - Italy.
November 2009 - October 2012: Università degli Studi dell’Aquila – L’Aquila: PhD Student, Biotechnology
February 2007 - July 2009: "Sapienza" University of Rome – Rome, Master's degree, Medical Molecular and Cellular Biotechnology, magna cum laude.
October 2003 - February 2007: "Sapienza" University of Rome – Rome, Bachelor's degree, Biotechnology, magna cum laude.

MAIN RESEARCH LINES
Metabolic reprogramming: study of the role of aerobic glycolysis in the proliferation and growth of normal and tumor cells;
Energy sensors: examining the biochemical mechanisms of action of the energy sensor AMPK in the pathogenesis of tumors;
NADH homeostasis: investigating the molecular mechanism of action of the antidiabetic drug phenformin as anticancer agent;
Metabolic targeting: study of pharmacological inhibitors in glucose, redox and energy pathways;
Drug design and biological validation: screening and identification of new bioactive compounds for cancer therapy.

COLLABORATIONS
Department of Chemistry and Pharmaceutical Technologies, "Sapienza" University of Rome; Department of Chemistry, "Sapienza" University of Rome; Department of Biochemistry, "Sapienza" University of Rome; Department of Sensory Organs, "Sapienza" University of Rome
Division of Metabolism and Research Unit of Metabolic Biochemistry, Bambino Gesù Pediatric Hospital, Rome; Department of Experimental Medicine, "Sapienza" University of Rome.

FIVE SELECTED PUBLICATIONS
1) Di Magno L, Manzi D, D'Amico D, Coni S, Macone A, Infante P, Di Marcotullio L, De Smaele E, Ferretti E, Screpanti I, Agostinelli E, Gulino A, Canettieri G. Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth.
Cell Cycle. 2014;13(21):3404-13.
2) Di Magno L, Basile A, Coni S, Manni S, Sdruscia G, D'Amico D, Antonucci L, Infante P, De Smaele E, Cucchi D, Ferretti E, Di Marcotullio L, Screpanti I, Canettieri G. The energy sensor AMPK regulates Hedgehog signaling in human cells through a unique Gli1 metabolic checkpoint.
Oncotarget. 2016 Feb 23;7(8):9538-49.
3) Di Magno L, Manni S, Di Pastena F, Coni S, Macone A, Cairoli S, Sambucci M, Infante P,
Moretti M, Petroni M, Nicoletti C, Capalbo C, De Smaele E, Di Marcotullio L, Giannini G, Battistini L, Goffredo BM, Iorio E, Agostinelli E, Maroder M, Canettieri G. Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module.
Cell Rep. 2020 Feb 11;30(6):1735-1752.e7. doi: 10.1016/j.celrep.2020.01.024.
4) Di Magno L, Coluccia A, Bufano M, Ripa S, La Regina G, Nalli M, Di Pastena F, Canettieri G, Silvestri R, Frati L. Discovery of novel human lactate dehydrogenase inhibitors: Structure based virtual screening studies and biological assessment.
Eur J Med Chem. 2022 Oct 5;240:114605. doi: 10.1016/j.ejmech.2022.114605. Epub 2022 Jul 14.
5) Di Magno L, Di Pastena F, Puxeddu M, La Regina G, Coluccia A, Ciogli A, Manetto S, Maroder M, Canettieri G, Silvestri R, Nalli M. Sulfonamide Inhibitors of β-Catenin Signaling as Anticancer Agents with Different Output on c-MYC.
ChemMedChem. 2020 Dec 3;15(23):2264-2268. doi: 10.1002/cmdc.202000594.